Encainide

Использование

Clinical use of encainide is primarily associated with the presence of serious ventricular tachycardia; however, like flecainide, it is also sufficiently effective for atrial arrhythmia and is used for natural occurrences.

Всемирная организация здравоохранения(ВОЗ)

The membrane-stabilizing antiarrhythmic agent encainide was introduced into medicine in the mid-1980's. The decision to delete the indications for patients with asymptomatic and less severe symptomatic ventricular arrhythmias was taken on the basis of the results of a trial (CAST study) that showed a two-fold increase in deaths in post-myocardiac patients taking encainide compared with the placebo group. (See also WHO comment for flecainide).